What I'm MOST thankful for is that Ponatinib was not the FIRST drug in Ariad's pipeline and they partnered it with Merck, and Ariad went it along with Rida as their second drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.